MedTrace Logo

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

NCT01118351 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2019-05-01

Study results available
· View outcomes & findings →

Summary

RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.

PURPOSE: This phase II trial is studying how well sunitinib malate works in treating patients with recurrent transitional cell bladder cancer.

Conditions

  • Recurrent Bladder Cancer
  • Transitional Cell Carcinoma of the Bladder

Interventions

DRUG

sunitinib malate

Given orally

OTHER

immunohistochemistry staining method

Correlative studies

OTHER

TdT-mediated dUTP nick end labeling assay

Correlative studies

OTHER

light microscopy

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Case Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Jorge Garcia, MD · Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2012-07-31
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01118351 on ClinicalTrials.gov